Back to Search
Start Over
Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation
- Source :
- Business Wire. December 19, 2013
- Publication Year :
- 2013
-
Abstract
- -Mean absolute treatment difference in lung function across all patients was 2.1 percentage points (p=0.20) and mean relative treatment difference was 5.0% (p=0.06)(n=69); study did not meet its primary endpoint- [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.353399673